Glucose-6-phosphate dehydrogenase deficiency presents a significant challenge in the treatment of vivax malaria, as the standard therapy, primaquine, can induce severe hemolysis in affected individuals. This review explores the current landscape of G6PD deficiency testing and its implications for radical cure treatment in vivax malaria. While traditional laboratory-based tests have been the gold standard, recent advancements in point-of-care testing offer rapid and accurate results, overcoming many barriers to accessibility. Technologies such as lateral flow assays and quantitative G6PD assays provide real-time insights into enzyme deficiency, aiding in personalized treatment decisions. Moreover, molecular diagnostics, including next-generation sequencing offer valuable genetic information for risk stratification and genetic counseling. Despite these advancements, challenges in implementing these technologies persist, particularly in resource-limited settings. Collaborative efforts are essential to address these challenges and optimize the management of vivax malaria in G6PD-deficient populations, contributing to global malaria elimination efforts.
HTML PDFShare this article
Malaria Control & Elimination received 1187 citations as per Google Scholar report
